Back to News
Market Impact: 0.25
Jade Biosciences Advances JADE301 Toward Phase 1 Trial In Dermatomyositis
Source: Nasdaq
Healthcare & BiotechProduct Launches
Jade Biosciences is preparing JADE301 for human testing after preclinical data indicated the investigational antibody selectively blocks IFN-Beta, a signaling protein implicated in dermatomyositis. The transition toward clinical development is a positive early-stage pipeline milestone, though efficacy and safety remain unproven in humans.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
JBIO0.55
More News
- Google rolls out Gemini 4 Argon, its most advanced AI model
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- Meta stock enjoys best month since 2022 on AI momentum
- Bloomberg Tech: OpenAI Seeks $30B as Trump Backs Safety Audits
- OpenAI’s $30B Bet, Trump’s AI Safety Shift and Apple’s Next Act
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ